The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand.

IF 3.4 2区 医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-25 DOI:10.1186/s12885-025-13724-w
Phanchaporn Wongmaneerung, Imjai Chitapanarux, Patrinee Traisathit, Sukon Prasitwattanaseree, Wisanu Rottuntikarn, Areewan Somwangprasert, Chagkrit Ditsatham, Kirati Watcharachan, Pitchayaponne Klunklin, Wimrak Onchan
{"title":"The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand.","authors":"Phanchaporn Wongmaneerung, Imjai Chitapanarux, Patrinee Traisathit, Sukon Prasitwattanaseree, Wisanu Rottuntikarn, Areewan Somwangprasert, Chagkrit Ditsatham, Kirati Watcharachan, Pitchayaponne Klunklin, Wimrak Onchan","doi":"10.1186/s12885-025-13724-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a major health concern worldwide, and Ki-67 level index is a prognostic factor that indicates tumor proliferation and predicts survival outcomes. However, the standard Ki 67 cut-off level varies between local laboratories, and in Thailand, there is no established optimal cut-off level.</p><p><strong>Objective: </strong>This study aimed to determine the optimal cut-off point for Ki-67 expression and investigate the association between Ki-67 levels and other prognostic factors with 8-year overall survival.</p><p><strong>Method: </strong>A retrospective review of Ki-67 levels was conducted in non-metastatic breast cancer patients treated at Maharaj Nakorn Chiangmai hospital from January 2013-December 2015, including 507 breast cancer patients.</p><p><strong>Results: </strong>The ROC curve analysis identified the optimal Ki-67 cut-point as ≥ 30%, with 75% sensitivity and 48.85% specificity. Age over 60 was associated with higher mortality regardless of cancer stage. Locally advanced staging, nodal involvement, Ki-67 ≥ 30%, and triple-negative subtype correlated with poorer survival. Even after adjustments, these factors remained significant in prognostic evaluation. Chemotherapy notably improved survival, especially in high Ki-67 (≥ 30) patients. However, this effect was not seen in low Ki-67 patients. High Ki-67 patients receiving chemotherapy showed improved survival in early-stage, node-negative cases compared to those who did not receive chemotherapy. HER2-positive patients with high Ki-67 benefited from chemotherapy, but statistical significance was not reached in hormone-positive patients.</p><p><strong>Conclusion: </strong>This study identified the optimal cut point for Ki-67 in Northern Thailand as 30%. Patients with KI-67 above 30% show significantly lower 8-year survival rates. This is especially relevant for low-risk patients, like those with hormonal subtypes or early-stage nodal negativity. In these cases, KI-67 becomes crucial for treatment decisions. Our study not only aids Northern Thailand's understanding but also aligns with broader research, emphasizing KI-67's vital role in planning treatment for low-risk breast cancer patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"346"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863483/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13724-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer is a major health concern worldwide, and Ki-67 level index is a prognostic factor that indicates tumor proliferation and predicts survival outcomes. However, the standard Ki 67 cut-off level varies between local laboratories, and in Thailand, there is no established optimal cut-off level.

Objective: This study aimed to determine the optimal cut-off point for Ki-67 expression and investigate the association between Ki-67 levels and other prognostic factors with 8-year overall survival.

Method: A retrospective review of Ki-67 levels was conducted in non-metastatic breast cancer patients treated at Maharaj Nakorn Chiangmai hospital from January 2013-December 2015, including 507 breast cancer patients.

Results: The ROC curve analysis identified the optimal Ki-67 cut-point as ≥ 30%, with 75% sensitivity and 48.85% specificity. Age over 60 was associated with higher mortality regardless of cancer stage. Locally advanced staging, nodal involvement, Ki-67 ≥ 30%, and triple-negative subtype correlated with poorer survival. Even after adjustments, these factors remained significant in prognostic evaluation. Chemotherapy notably improved survival, especially in high Ki-67 (≥ 30) patients. However, this effect was not seen in low Ki-67 patients. High Ki-67 patients receiving chemotherapy showed improved survival in early-stage, node-negative cases compared to those who did not receive chemotherapy. HER2-positive patients with high Ki-67 benefited from chemotherapy, but statistical significance was not reached in hormone-positive patients.

Conclusion: This study identified the optimal cut point for Ki-67 in Northern Thailand as 30%. Patients with KI-67 above 30% show significantly lower 8-year survival rates. This is especially relevant for low-risk patients, like those with hormonal subtypes or early-stage nodal negativity. In these cases, KI-67 becomes crucial for treatment decisions. Our study not only aids Northern Thailand's understanding but also aligns with broader research, emphasizing KI-67's vital role in planning treatment for low-risk breast cancer patients.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌亚型中Ki-67表达与生存之间的关系:泰国北部Ki-67切点的横断面研究
背景:乳腺癌是世界范围内的主要健康问题,Ki-67水平指数是指示肿瘤增殖和预测生存结果的预后因素。然而,标准Ki 67截止水平因地方实验室而异,在泰国,没有确定的最佳截止水平。目的:本研究旨在确定Ki-67表达的最佳临界值,并探讨Ki-67水平与其他预后因素与8年总生存期的关系。方法:回顾性分析2013年1月至2015年12月在清迈Maharaj Nakorn医院治疗的非转移性乳腺癌患者的Ki-67水平,其中包括507例乳腺癌患者。结果:ROC曲线分析确定Ki-67最佳切点≥30%,敏感性75%,特异性48.85%。无论癌症分期如何,60岁以上的人死亡率都较高。局部晚期、淋巴结受累、Ki-67≥30%和三阴性亚型与较差的生存率相关。即使经过调整,这些因素在预后评估中仍然很重要。化疗显著提高了生存率,尤其是Ki-67高(≥30)患者。然而,这种效果在低Ki-67患者中未见。与未接受化疗的患者相比,接受化疗的高Ki-67患者在早期淋巴结阴性病例中生存率提高。高Ki-67的her2阳性患者受益于化疗,但激素阳性患者未达到统计学意义。结论:本研究确定泰国北部Ki-67的最佳切点为30%。KI-67≥30%的患者8年生存率明显降低。这对低风险患者尤其重要,比如那些激素亚型或早期淋巴结阴性的患者。在这些病例中,KI-67对治疗决定至关重要。我们的研究不仅有助于泰国北部的理解,而且与更广泛的研究保持一致,强调KI-67在规划低风险乳腺癌患者治疗中的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
期刊最新文献
Exploring psychological distress, appraisal, and coping during the scan result journey: a qualitative study of young and middle-aged Chinese adults with advanced cancer. The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer. Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer. Hospital-based patterns of esophageal and gastric cancer cases at a major tertiary referral center in Kabul, Afghanistan: a retrospective case series. Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1